Table 8. Talazoparib as monotherapy and combination therapy.

BRCA: breast cancer-associated; PALB2: partner and localizer of BRCA2; DDR: DNA damage repair; PFS: progression-free survival; OS: overall survival; ORR: objective response rate

Clinical trial	Phase	N	Study objective	Germline mutations	Somatic mutations	PFS	OS	ORR
Talazoparib monotherapy
NCT01286987 [55]	I	13	Evaluate safety and preliminary efficacy in advanced or recurrent solid tumors and study has 13 pancreatic cancer patients	BRCA2 PALB2	-	N/A		20%. Patients with response were bearing DDR mutations
Talalzoparib with combination with immunotherapy and targeted therapy
NCT03637491 [56]	Ib/II		Evaluate and efficacy of avelumab, binimetinib and talazoparib combinations in patients with locally advanced or metastatic Ras-mutant solid tumors including pancreatic cancer pts	DDR mutations will be assessed at baseline		Currently terminated